---
document_datetime: 2025-12-29 08:18:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zokinvy.html
document_name: zokinvy.html
version: success
processing_time: 0.1080382
conversion_datetime: 2025-12-31 04:44:49.302199
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zokinvy

[RSS](/en/individual-human-medicine.xml/67584)

##### Authorised

This medicine is authorised for use in the European Union

lonafarnib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zokinvy](#news-on)
- [More information on Zokinvy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zokinvy is a medicine used to treat patients of 12 months and older who are affected by the following rare diseases in which features resembling aging appear in childhood:

- Hutchinson-Gilford progeria syndrome;
- processing-deficient progeroid laminopathies.

The diseases that Zokinvy is used to treat are rare and Zokinvy was designated as 'orphan medicine' on [14 December 2018](/en/medicines/human/orphan-designations/eu-3-18-2118) for Hutchinson-Gilford progeria syndrome.

Zokinvy contains the active substance lonafarnib.

Expand section

Collapse section

## How is Zokinvy used?

Zokinvy can only be obtained with a prescription and treatment should be initiated by doctors with experience in the treatment of patients with premature aging or rare metabolic conditions.

Zokinvy is available as capsules to be taken with food twice a day. The starting daily dose (which ranges from 75 to 225 mg) depends on the height and weight of the patient. After 4 months of treatment, the patient may start taking a higher (maintenance) dose.

For more information about using Zokinvy, see the package leaflet or contact your doctor or pharmacist.

## How does Zokinvy work?

Patients with Hutchinson-Gilford progeria syndrome and with processing-deficient progeroid laminopathies have an accumulation of abnormal forms of progerin or progerin-like proteins, which causes damage to cells and leads to symptoms of aging early in life. Zokinvy prevents a chemical reaction involved in the formation of these abnormal proteins, thereby helping to improve symptoms of the diseases.

## What benefits of Zokinvy have been shown in studies?

Two main studies have shown that Zokinvy prolongs the life of patients with Hutchinson-Gilford progeria syndrome and with processing-deficient progeroid laminopathies. The studies involved 62 patients who were given Zokinvy. Three years after start of treatment with Zokinvy only, the patients lived between 2.5 months and about half a year longer than the 62 patients who did not participate in the studies and were not given Zokinvy. At the time of the last follow-up (about 11 years after starting treatment), patients given Zokinvy (and possibly additional treatments) lived an average of 4.3 years longer than untreated patients. However, given the limited data available, the extra years lived could be as low as 2.6 years.

## What are the risks associated with Zokinvy?

The most common side effects with Zokinvy (which may affect more than 1 in 10 people) are vomiting, diarrhoea, increased levels of liver enzymes, decreased appetite, nausea, abdominal pain, tiredness, weight loss, constipation and upper respiratory tract infection (nose and throat infection).

The most common serious side effects with Zokinvy (which may affect up to 1 in 10 people) are increased levels of liver enzymes, cerebral ischaemia (reduced blood supply to the brain), fever and dehydration.

## Why is Zokinvy authorised in the EU?

At the time of the authorisation of Zokinvy there were no other medicines for treating Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The results from the studies of Zokinvy showed that this medicine can prolong the life of patients with these conditions. The most common side effects, such as diarrhoea, nausea, and vomiting, occurred mainly in the first 4 months of treatment and were manageable.

The European Medicines Agency therefore decided that Zokinvy's benefits are greater than its risks and it can be authorised for use in the EU under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Zokinvy due to the rarity of the disease.

Every year, the European Medicines Agency will review any new information that becomes available, and this overview will be updated as necessary.

## What information is still awaited for Zokinvy?

Since Zokinvy has been authorised under exceptional circumstances, the company that markets Zokinvy will provide data from a registry of patients treated with the medicine to further evaluate the safety and effectiveness of Zokinvy as well as the quality of life of patients.

## What measures are being taken to ensure the safe and effective use of Zokinvy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zokinvy have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zokinvy are continuously monitored. Suspected side effects reported with Zokinvy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zokinvy

Zokinvy received a marketing authorisation valid throughout the EU on 18 July 2022.

Zokinvy: EPAR - Medicine overview

Reference Number: EMA/351469/2022

English (EN) (143.11 KB - PDF)

**First published:** 01/08/2022

[View](/en/documents/overview/zokinvy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-632)

български (BG) (169.05 KB - PDF)

**First published:**

01/08/2022

[View](/bg/documents/overview/zokinvy-epar-medicine-overview_bg.pdf)

español (ES) (142.52 KB - PDF)

**First published:**

01/08/2022

[View](/es/documents/overview/zokinvy-epar-medicine-overview_es.pdf)

čeština (CS) (155.79 KB - PDF)

**First published:**

01/08/2022

[View](/cs/documents/overview/zokinvy-epar-medicine-overview_cs.pdf)

dansk (DA) (142.26 KB - PDF)

**First published:**

01/08/2022

[View](/da/documents/overview/zokinvy-epar-medicine-overview_da.pdf)

Deutsch (DE) (146 KB - PDF)

**First published:**

01/08/2022

[View](/de/documents/overview/zokinvy-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.56 KB - PDF)

**First published:**

01/08/2022

[View](/et/documents/overview/zokinvy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (167.52 KB - PDF)

**First published:**

01/08/2022

[View](/el/documents/overview/zokinvy-epar-medicine-overview_el.pdf)

français (FR) (143.64 KB - PDF)

**First published:**

01/08/2022

[View](/fr/documents/overview/zokinvy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.14 KB - PDF)

**First published:**

01/08/2022

[View](/hr/documents/overview/zokinvy-epar-medicine-overview_hr.pdf)

italiano (IT) (141.72 KB - PDF)

**First published:**

01/08/2022

[View](/it/documents/overview/zokinvy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (171.3 KB - PDF)

**First published:**

01/08/2022

[View](/lv/documents/overview/zokinvy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.04 KB - PDF)

**First published:**

01/08/2022

[View](/lt/documents/overview/zokinvy-epar-medicine-overview_lt.pdf)

magyar (HU) (164.14 KB - PDF)

**First published:**

01/08/2022

[View](/hu/documents/overview/zokinvy-epar-medicine-overview_hu.pdf)

Malti (MT) (168.95 KB - PDF)

**First published:**

01/08/2022

[View](/mt/documents/overview/zokinvy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (144.74 KB - PDF)

**First published:**

01/08/2022

[View](/nl/documents/overview/zokinvy-epar-medicine-overview_nl.pdf)

polski (PL) (171.16 KB - PDF)

**First published:**

01/08/2022

[View](/pl/documents/overview/zokinvy-epar-medicine-overview_pl.pdf)

português (PT) (132.88 KB - PDF)

**First published:**

01/08/2022

[View](/pt/documents/overview/zokinvy-epar-medicine-overview_pt.pdf)

română (RO) (162.48 KB - PDF)

**First published:**

01/08/2022

[View](/ro/documents/overview/zokinvy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (155.81 KB - PDF)

**First published:**

01/08/2022

[View](/sk/documents/overview/zokinvy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.67 KB - PDF)

**First published:**

01/08/2022

[View](/sl/documents/overview/zokinvy-epar-medicine-overview_sl.pdf)

Suomi (FI) (139.97 KB - PDF)

**First published:**

01/08/2022

[View](/fi/documents/overview/zokinvy-epar-medicine-overview_fi.pdf)

svenska (SV) (140.96 KB - PDF)

**First published:**

01/08/2022

[View](/sv/documents/overview/zokinvy-epar-medicine-overview_sv.pdf)

Zokinvy : EPAR - Risk-management-plan summary

English (EN) (163.88 KB - PDF)

**First published:** 01/08/2022

[View](/en/documents/rmp-summary/zokinvy-epar-risk-management-plan-summary_en.pdf)

## Product information

Zokinvy : EPAR - Product information

English (EN) (900.73 KB - PDF)

**First published:** 01/08/2022

**Last updated:** 06/01/2025

[View](/en/documents/product-information/zokinvy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-836)

български (BG) (1 MB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/bg/documents/product-information/zokinvy-epar-product-information_bg.pdf)

español (ES) (959.49 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/es/documents/product-information/zokinvy-epar-product-information_es.pdf)

čeština (CS) (994.06 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/cs/documents/product-information/zokinvy-epar-product-information_cs.pdf)

dansk (DA) (940.1 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/da/documents/product-information/zokinvy-epar-product-information_da.pdf)

Deutsch (DE) (956.22 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/de/documents/product-information/zokinvy-epar-product-information_de.pdf)

eesti keel (ET) (940.21 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/et/documents/product-information/zokinvy-epar-product-information_et.pdf)

ελληνικά (EL) (1.01 MB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/el/documents/product-information/zokinvy-epar-product-information_el.pdf)

français (FR) (954.89 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/fr/documents/product-information/zokinvy-epar-product-information_fr.pdf)

hrvatski (HR) (1007.08 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/hr/documents/product-information/zokinvy-epar-product-information_hr.pdf)

íslenska (IS) (819.79 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/is/documents/product-information/zokinvy-epar-product-information_is.pdf)

italiano (IT) (972.04 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/it/documents/product-information/zokinvy-epar-product-information_it.pdf)

latviešu valoda (LV) (985.3 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/lv/documents/product-information/zokinvy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (998.24 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/lt/documents/product-information/zokinvy-epar-product-information_lt.pdf)

magyar (HU) (992.23 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/hu/documents/product-information/zokinvy-epar-product-information_hu.pdf)

Malti (MT) (1023.16 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/mt/documents/product-information/zokinvy-epar-product-information_mt.pdf)

Nederlands (NL) (949.75 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/nl/documents/product-information/zokinvy-epar-product-information_nl.pdf)

norsk (NO) (820.83 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/no/documents/product-information/zokinvy-epar-product-information_no.pdf)

polski (PL) (989.04 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/pl/documents/product-information/zokinvy-epar-product-information_pl.pdf)

português (PT) (908.41 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/pt/documents/product-information/zokinvy-epar-product-information_pt.pdf)

română (RO) (993.07 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/ro/documents/product-information/zokinvy-epar-product-information_ro.pdf)

slovenčina (SK) (1005.3 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/sk/documents/product-information/zokinvy-epar-product-information_sk.pdf)

slovenščina (SL) (1022.75 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/sl/documents/product-information/zokinvy-epar-product-information_sl.pdf)

Suomi (FI) (941.65 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/fi/documents/product-information/zokinvy-epar-product-information_fi.pdf)

svenska (SV) (935.03 KB - PDF)

**First published:**

01/08/2022

**Last updated:**

06/01/2025

[View](/sv/documents/product-information/zokinvy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0011 21/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zokinvy : EPAR - All authorised presentations

English (EN) (50.1 KB - PDF)

**First published:** 01/08/2022

[View](/en/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-788)

български (BG) (61.34 KB - PDF)

**First published:**

01/08/2022

[View](/bg/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_bg.pdf)

español (ES) (55.08 KB - PDF)

**First published:**

01/08/2022

[View](/es/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.25 KB - PDF)

**First published:**

01/08/2022

[View](/cs/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (67.85 KB - PDF)

**First published:**

01/08/2022

[View](/da/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.71 KB - PDF)

**First published:**

01/08/2022

[View](/de/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.83 KB - PDF)

**First published:**

01/08/2022

[View](/et/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.41 KB - PDF)

**First published:**

01/08/2022

[View](/el/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_el.pdf)

français (FR) (54.68 KB - PDF)

**First published:**

01/08/2022

[View](/fr/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.13 KB - PDF)

**First published:**

01/08/2022

[View](/hr/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.89 KB - PDF)

**First published:**

01/08/2022

[View](/is/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (54.73 KB - PDF)

**First published:**

01/08/2022

[View](/it/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.02 KB - PDF)

**First published:**

01/08/2022

[View](/lv/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.35 KB - PDF)

**First published:**

01/08/2022

[View](/lt/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.59 KB - PDF)

**First published:**

01/08/2022

[View](/hu/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.44 KB - PDF)

**First published:**

01/08/2022

[View](/mt/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (53.56 KB - PDF)

**First published:**

01/08/2022

[View](/nl/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.81 KB - PDF)

**First published:**

01/08/2022

[View](/no/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.7 KB - PDF)

**First published:**

01/08/2022

[View](/pl/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_pl.pdf)

português (PT) (53.18 KB - PDF)

**First published:**

01/08/2022

[View](/pt/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.39 KB - PDF)

**First published:**

01/08/2022

[View](/ro/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (69.61 KB - PDF)

**First published:**

01/08/2022

[View](/sk/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.14 KB - PDF)

**First published:**

01/08/2022

[View](/sl/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (54.01 KB - PDF)

**First published:**

01/08/2022

[View](/fi/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (52.99 KB - PDF)

**First published:**

01/08/2022

[View](/sv/documents/all-authorised-presentations/zokinvy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zokinvy Active substance Lonafarnib International non-proprietary name (INN) or common name lonafarnib Therapeutic area (MeSH)

- Progeria
- Laminopathies

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.

## Authorisation details

EMA product number EMEA/H/C/005271

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

TMC Pharma (EU) Limited

G24A Arc Labs Research and Innovation Centre SETU West Campus, Carriganore Waterford X91 P20H IRELAND

Opinion adopted 19/05/2022 Marketing authorisation issued 18/07/2022 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zokinvy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.85 KB - PDF)

**First published:** 24/03/2023

**Last updated:** 06/01/2025

[View](/en/documents/procedural-steps-after/zokinvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zokinvy : Orphan maintenance assessment report (initial authorisation)

Adopted

English (EN) (214.95 KB - PDF)

**First published:** 01/08/2022

[View](/en/documents/orphan-maintenance-report/zokinvy-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Zokinvy : EPAR - Public assessment report

Adopted

Reference Number: EMA/656670/2022 Rev.1

English (EN) (1.85 MB - PDF)

**First published:** 01/08/2022

**Last updated:** 13/12/2022

[View](/en/documents/assessment-report/zokinvy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zokinvy

Adopted

Reference Number: EMA/CHMP/264223/2022

English (EN) (160.93 KB - PDF)

**First published:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zokinvy_en.pdf)

#### News on Zokinvy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

[First treatment for children with Progeria or progeroid like syndromes (rare premature aging syndromes)](/en/news/first-treatment-children-progeria-or-progeroid-syndromes-rare-premature-aging-syndromes) 20/05/2022

#### More information on Zokinvy

- [EU/3/18/2118 - orphan designation for treatment of Hutchinson-Gilford progeria](/en/medicines/human/orphan-designations/eu-3-18-2118)

**This page was last updated on** 06/01/2025

## Share this page

[Back to top](#main-content)